Balance Sheet (Annual)

BSFT / BroadSoft, Inc. Balance Sheet shows account balances for the company at points in time. Balance Sheet data includes Assets, Current Assets, Fixed Assets, Property, Plant and Equipment (PPE), Inventory, Intangibles, Liabilities, Current Liabilities, Debt, Capital Lease Obligations, Common Stock, Retained Earnings, Treasury Stock, and Shareholders Equity.

All numbers are times 1,000 except per share units.

2011 2012 2013 2014 2015 2016
Assets
  Assets Current
    Cash And Cash Equivalents At Carrying Value 94,072 90,545 69,866 101,543 175,857 82,993
    Short Term Investments 92,749 73,075 93,664 68,923 72,531 136,428
    Accounts Receivable Net Current 47,048 48,980 66,595 81,794 108,113 121,817
    Other Assets Current 4,435 10,796 12,597 12,678 13,155 17,431
    Assets Current 251,272 227,128 247,281 279,240 369,656 358,669
  Assets Noncurrent
    Property Plant And Equipment Net 4,221 7,361 10,110 14,363 19,481 22,626
    Long Term Investments 5,000 30,102 23,340 52,030 102,385 144,159
    Finite Lived Intangible Assets Net 8,842 11,247 20,390 15,568 18,835 27,839
    Goodwill 17,276 37,529 65,192 65,303 72,275 82,758
    Deferred Tax Assets Net Noncurrent - - 16,482 10,495 1,661 7,042
    Other Assets Noncurrent 3,386 12,955 8,121 8,279 8,081 8,107
    Assets Noncurrent 39,684 99,778 144,216 166,055 222,718 292,531
  Assets 290,956 326,906 391,497 445,295 592,374 651,200
Liabilities And Stockholders Equity
  Liabilities Current
    Convertible Debt Current - - - - - -
    Accounts Payable And Accrued Liabilities Current 14,999 15,686 14,957 21,222 28,667 33,854
    Deferred Revenue Current 55,372 49,368 71,258 87,423 106,483 97,037
    Liabilities Current 71,262 65,609 86,215 108,645 135,150 130,891
  Convertible Debt Noncurrent 81,737 86,451 91,549 97,049 188,331 201,015
  Deferred Revenue Noncurrent 1,764 11,781 6,404 14,033 4,571 12,152
  Other Liabilities Noncurrent 1,056 1,416 3,312 4,030 7,289 5,908
  Liabilities 157,713 165,671 190,986 225,046 335,341 349,966
  Commitments And Contingencies - - - - - -
  Stockholders Equity Including Portion Attributable To Noncontrolling Interest
    Preferred Stock Value - - 0 0 0 0
    Common Stock Value 271 279 283 290 291 304
    Additional Paid In Capital Common Stock 191,714 208,073 254,736 279,642 333,153 383,268
    Accumulated Other Comprehensive Income Loss Net Of Tax -2,557 -3,008 -1,525 -7,712 -13,810 -21,845
    Retained Earnings Accumulated Deficit -56,185 -44,109 -52,983 -51,971 -62,601 -60,493
    Stockholders Equity Including Portion Attributable To Noncontrolling Interest 133,243 161,235 200,511 220,249 257,033 301,234
  Liabilities And Stockholders Equity 290,956 326,906 391,497 445,295 592,374 651,200

Peers - Prepackaged Software (7372)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 11133B409